TheStreet tracks the top 10 clinical trials to watch

TheStreet's top biotech stock ace, Adam Feuerstein, has culled through a mountain of releases and reports to come up with the 10 most closely-watched trial announcements expected in the second half of the year. His list includes: Ariad's Phase III data for the sarcoma drug ridaforolimus, which Merck licensed; AstraZeneca's zibotentan, which hopes to answer the question about who has the next Provenge to offer the market; as well as mid-stage data on BioMarin's Peg-Pal for phenylketonuria,...

The ASCO roundup: ArQule drug flunks a mid-stage test

Plenty of more early-stage and mid-stage study results came to light at ASCO over the past day. Here are some of the highlights: ArQule said that its lung cancer drug flunked a mid-stage study, but it flagged some positive results for a subset of patients taking the therapy. About two thirds of the patients taking a combination of ARQ-197 and Tarceva demonstrated an improvement in survival rates, but that wasn't enough to give it a significant statistical edge over Tarceva alone. Patients...